The EMAS 2008 update on clinical recommendations on postmenopausal hormone replacement therapy

Area of Science:

• Reproductive Endocrinology
• Menopause Management
• Pharmacology

Background:

• Hormone therapy remains a primary treatment for menopausal symptoms and estrogen deficiency.
• The decision to use hormone therapy involves balancing potential benefits against known risks.
• Media coverage has inconsistently represented the benefits and risks of hormone therapy, necessitating updated scientific consensus.

Purpose of the Study:

• To provide an updated statement on hormone replacement therapy (HRT) use.
• To consolidate current scientific knowledge on HRT benefits and risks.
• To guide clinicians and patients in the complex decision-making process for HRT.

Main Methods:

• Review and synthesis of recent scientific literature on hormone therapy.
• Analysis of clinical trial data and epidemiological studies.
• Expert consensus and guideline development by the European Menopause and Andropause Society (EMAS).

Main Results:

• The updated statement addresses the nuanced benefits of HRT for menopausal symptom relief.
• It critically evaluates the risks associated with HRT, considering recent evidence.
• The guidance emphasizes individualized treatment approaches based on risk-benefit assessment.

Conclusions:

• Hormone therapy continues to be a valuable tool for managing menopausal symptoms.
• A regular update of scientific knowledge is crucial for informed HRT prescription.
• This EMAS statement provides current recommendations for the safe and effective use of hormone replacement therapy.